Moreover, Ctla-4-Ig treatment significantly reduced the expression of pro-inflammatory genes, including il13, tnfa, mpx, mmp9, and cxcl8a, as well as igfbp1a, cremb, and lsp1a, which are susceptibility genes for IBD observed in mammals (Figure 8C and D). Here, CTLA4 is linked to inflammatory bowel disease.